Dear Client,
As part of our ongoing commitment to ensuring the security of your online trading experience, we would like to inform you of our protocol for addressing any suspicious activities observed on your trading account
Should you notice any irregularities or suspect unauthorized access to your account, we kindly request that you take immediate action by following the steps outlined below:
Send an Email Please send an email to stoptrade@acml.in from your registered email ID. In the email, briefly outline the suspicious activity you have observed.
Phone Call Alternatively, you can call us at 07968101000 Ext: 1 from your registered mobile number. This will enable us to address your concerns promptly.
When contacting us, please ensure you provide the following details:
By providing this information, you enable us to swiftly investigate and take appropriate measures to safeguard your account.
Your security and peace of mind are of utmost importance to us, and we appreciate your cooperation in maintaining the integrity of your trading account.
On conclusion of the inspection, the company received one observation in the Form-483.
The company believes that the observation is procedural in nature. The company is confident to address this observation comprehensively.
NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.
The company's consolidated net profit increased 5.3% to Rs 406.60 crore on 14.3% jump in revenue from operations to Rs 1,221 crore in Q4 FY25 over Q4 FY24.
The scrip had declined 1.26% to end at Rs 912.55 on the BSE on Friday.
Powered by Capital Market - Live News